1167 completed, 830 unknown, 534 recruiting, 209 terminated. 1088 Phase 2, 658 Phase 1, 577 Not applicable, 301 Phase 3, 66 Phase 4.
Follow Stomach Neoplasms: new trials by email Literature Review of Stomach Neoplasms trials Research Report on Stomach Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 3 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 820 | 2027-06-30 | 2026-09-29 |
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer Gastric Cancer | Not yet recruiting | Liu Yang | 300 | 2027-02-01 | 2026-07-13 | |
| Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE) Zolbetuximab Exposure, Platinum-based Chemotherapy Exposure, 1L Treatment Not Containing Zolbetuximab Exposure - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Not yet recruiting | Astellas Pharma Europe Ltd. | 1000 | 2027-01-31 | 2026-10-28 | |
| TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE) Music-assisted relaxation and imagery (MARI) - Surgery, Stomach Cancer | Not applicable | Not yet recruiting | Case Comprehensive Cancer Center | 20 | 2027-01-01 | 2026-08-05 |
| Lymph Node Metastasis Pattern After Neoadjuvant Chemoimmunotherapy in LAGC Neoadjuvant SOX chemotherapy combined with PD-1 inhibitor - Stomach Neoplasms, Gastric Cancer (Diagnosis) | Not yet recruiting | Hainan General Hospital | 103 | 2027-01-01 | 2026-10-28 | |
| Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer Apatinib Mesylate Tablets - Gastric Cancer, Surgery | Phase 3 | Not yet recruiting | Fujian Medical University | 118 | 2026-12-25 | 2026-01-02 |
| Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction Adenocarcinoma Serplulimab, Docetaxel, Oxaliplatin, S1, and Lenvatinib combined with PIPAC - Gastric/Gastroesophageal Junction Adenocarcinoma, Oligometastatic Peritoneal Metastasis | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 42 | 2026-12-15 | 2026-10-29 |
| Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy Radical Gastrectomy with D2 Lymphadenectomy, Standard Systemic Therapy for Advanced Gastric Cancer - Gastric Cancer, Peritoneal Metastasis | Phase 3 | Recruiting | Hua Huang, MD, PhD | 170 | 2026-12-01 | 2026-10-16 |
| A Study of Trifluridine/Tipiracil (TAS-102) Combined With Nedaplatin for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Refractory to ≥ Second-Line Chemotherapy TAS102+Nedaplatin - Gastric Cancer (GC) | Phase 2 | Not yet recruiting | Tao Zhang | 36 | 2026-12-01 | 2026-11-03 |
| SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors SND002 Cell Injection - Colorectal Neoplasms, Stomach Neoplasms | Phase 1 | Not yet recruiting | Guizhou Sinorda Pharmaceutical Co., Ltd. | 78 | 2026-12-01 | 2026-11-04 |
| A Study of LY4336619 in Adult Participants With Advanced Solid Tumors LY4336619, Sofetabart Mipitecan (Sofe-M) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 | Not yet recruiting | Eli Lilly and Company | 370 | 2026-12-01 | 2026-11-10 |
| HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers HLX22, Serplulimab, trastuzumab - Gastric Cancer (Diagnosis), Colorectal Cancer (Diagnosis) | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 128 | 2026-12-01 | 2026-11-16 |
| HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric Cancer HLX22, Trastuzumab, XELOX Chemotherapy - HER2-Positive, Limited Metastatic | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 30 | 2026-12-01 | 2026-11-17 |
| Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA Zanidatamab - Esophageal Cancer, GastroEsophageal Cancer | Not yet recruiting | Jazz Pharmaceuticals | 300 | 2026-11-30 | 2026-10-26 | |
| A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Phase 4 | Not yet recruiting | Astellas Pharma Global Development, Inc. | 50 | 2026-11-30 | 2026-09-21 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| Application of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric Cancer With Peritoneal Metastasis Retlirafusp alfa + nab-paclitaxel + apatinib, HEPIC - Gastric Cancer (Diagnosis) | Phase 2 | Not yet recruiting | Anhui Provincial Cancer Hospital | 32 | 2026-11-20 | 2026-10-29 |
| Biomarker Investigation for Early Gastric Cancer Detection Saliva sampling, Gastric juice sampling, Blood sampling - Gastro Oesophageal Cancer | Not applicable | Recruiting | Centre Leon Berard | 100 | 2026-11-12 | 2026-11-17 |
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
Showing 20 of 3190. Sign in to see all of them.
Esophageal Neoplasms (557) · Pancreatic Neoplasms (395) · Colorectal Neoplasms (371) · Breast Neoplasms (301) · Carcinoma, Non-Small-Cell Lung (234) · Ovarian Neoplasms (233) · Neoplasms (214) · Lung Neoplasms (204) · Colonic Neoplasms (199) · Carcinoma, Hepatocellular (153) · Neoplasm Metastasis (150) · Liver Neoplasms (145) · Urinary Bladder Neoplasms (144) · Uterine Cervical Neoplasms (135)
Digestive System Diseases (3184) · Neoplasms by Site (3180) · Stomach Diseases (3180) · Gastrointestinal Diseases (3175) · Digestive System Neoplasms (3171) · Gastrointestinal Neoplasms (3098) · Neoplasms (2976) · Intestinal Diseases (597) · Esophageal Diseases (587) · Neoplasms by Histologic Type (570) · Head and Neck Neoplasms (562) · Intestinal Neoplasms (555) · Endocrine System Diseases (548) · Endocrine Gland Neoplasms (539) · Colonic Diseases (534)
Oxaliplatin (307) · Capecitabine (218) · Fluorouracil (190) · Cisplatin (173) · Docetaxel (144) · S 1 (combination) (140) · Paclitaxel (130) · Leucovorin (122) · pembrolizumab (113) · Irinotecan (111) · Trastuzumab (81) · Nivolumab (64) · apatinib (59) · Drug Therapy (52) · sintilimab (48)
Yonsei University (64) · National Cancer Institute (NCI) (62) · Fudan University (53) · Fujian Medical University (47) · Memorial Sloan Kettering Cancer Center (37) · National Cancer Center, Korea (37) · Samsung Medical Center (36) · Peking University (33) · Tianjin Medical University Cancer Institute and Hospital (33) · Shanghai Zhongshan Hospital (28) · Asan Medical Center (27) · AstraZeneca (27) · Sun Yat-sen University (27) · The First Affiliated Hospital with Nanjing Medical University (27) · Hoffmann-La Roche (25)
China (1073) · United States (778) · South Korea (480) · Japan (179) · Spain (169) · France (156) · Italy (156) · Germany (155) · United Kingdom (154) · Taiwan (139) · Canada (107) · Australia (106) · Belgium (78) · Netherlands (77) · Poland (66)
Changming Huang, Professor (8) · Yelena Janjigian, MD (8) · Jiafu Ji, MD (6) · Lin Shen, MD (6) · Chen Li, PH D (5) · Han Liang, Master (5)
PMID 35623069, PMID 40341124, PMID 20728210, PMID 40340830, PMID 33538338, PMID 33792646, PMID 38421211, PMID 15273542, PMID 22226517, PMID 24714327, PMID 30982686, PMID 35219300, PMID 35692051, PMID 37037952, PMID 38308771, PMID 38980664, PMID 39089261, PMID 40117530, PMID 11813623, PMID 16822992, PMID 17978289, PMID 18669424, PMID 18948798, PMID 21104822, PMID 21444866, PMID 22189752, PMID 23207683, PMID 23403142, PMID 24094768, PMID 24399492, PMID 24618998, PMID 25240821, PMID 25939684, PMID 26352529, PMID 26542081, PMID 26566136, PMID 26808342, PMID 26857702, PMID 27156933, PMID 27641243, PMID 27776843, PMID 28716815, PMID 29543932, PMID 30557792, PMID 30566590, PMID 30911859, PMID 31513484, PMID 32101269, PMID 33763656, PMID 34197702
2023 (28), 2017 (12), 2019 (12), 2018 (11), 2014 (10), 2015 (9), 2025 (9), 2016 (7), P30CA033572 (6), P30CA016087 (5), P30CA068485 (5), U10CA032102 (5), 2009 (4), 2008 (3), P30CA008748 (3)